Docking studies: In silico aldose reductase inhibitory activity of commercially available flavonoids

5Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

New drugs for the inhibition of the enzyme aldose reductase are in development and they have to be screened before being considered for preclinical and clinical evaluation. The current study deals with the evaluation of the cyclooxygenase inhibitory activity of flavonoids using in silico docking studies. In this perspective, flavonoids like bergapten, buceracidin-B, dorsilurin-F, communin-A, and coumestrol were selected. Epalrestat, a known aldose reductase inhibitor was used as the standard. Docking results showed that all the selected flavonoids showed binding energy ranging between -7.91 kcal/mol to -5.08 kcal/mol when compared with that of the standard (-5.59 kcal/mol). Intermolecular energy (-9.11 kcal/mol to -8.66 kcal/mol) and inhibition constant (1.58 μM to 187.37 μM) of the ligands also coincide with the binding energy. Communin-A contributed better aldose reductase inhibitory activity because of its structural parameters.

Cite

CITATION STYLE

APA

Umamaheswari, M., Aji, C. S., Asokkumar, K., Sivashanmugam, T., Subhadradevi, V., Jagannath, P., & Madeswaran, A. (2012). Docking studies: In silico aldose reductase inhibitory activity of commercially available flavonoids. Bangladesh Journal of Pharmacology, 7(2), 108–113. https://doi.org/10.3329/bjp.v7i2.10779

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free